Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights
The call can be accessed by dialing (844) 296-7720 (
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com/events-and-presentations/upcoming-events. The webcast will be recorded and available for replay on the company's website for two weeks.
Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510 and its oral non-covalent BTK inhibitor vecabrutinib. SNS-510 is in IND-enabling studies and vecabrutinib is completing a Phase 1b trial in patients with advanced B cell malignancies.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
|Investor and Media Inquiries:|
Source: Sunesis Pharmaceuticals, Inc.